Veru Healthcare is the new company that is a result of the acquisition of Aspen Park Pharmaceuticals by The Female Health Company.
Veru Healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. To realize this goal, Veru Healthcare has three divisions: Pharmaceutical and Devices, Consumer Health Products, and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. Women’s Health has product candidates for female sexual health and advanced breast and ovarian cancers and markets FC2, a disposable contraceptive device, to OB GYN physicians and is the only female condom approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS and the Zika virus, and unintended pregnancy. The Female Health Company is tasked with managing the global public sector part of our business. Since The Female Health Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.